Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism. We now show that in a human xenograft melanoma model, oral MBZ is as effective as the current standard of care temozolomide in reducing tumor growth. Inhibition of melanoma growth in vivo is accompanied by phosphorylation of BCL2 and decreased levels of X-linked inhibitor of apoptosis (XIAP). Reduced expression of XIAP on treatment with MBZ is partially mediated by its proteasomal degradation. Furthermore, exposure of melanoma cells to MBZ promotes the interaction of SMAC/DIABLO with XIAP, thereby alleviating XIAP's inhibition on apoptosis. XIAP expression on exposure to MBZ is indicative of sensitivity to MBZ as MBZ-resistant cells do not show reduced levels of XIAP after treatment. Resistance to MBZ can be reversed partially by siRNA knockdown of cellular levels of XIAP.
Introduction
Melanoma is the most aggressive form of skin cancer, with a high propensity to metastasize. On the basis of National Cancer Institute estimates, the lifetime risk of an individual in the USA developing melanoma has doubled in the last 20 years [1] . Because the risk of developing melanoma may be correlated with UV exposure, and recent societal trends have resulted in increased sun exposure, the increasing trend is expected to continue its trajectory [2] . Despite recent advances in the treatment of melanoma using targeted therapies, patients still face a dismal prognosis as most responses are transient, with relapse and resistance occurring in most cases [3] . Temozolomide (TMZ), the standard of care for advanced nonmutant v-Raf murine sarcoma viral oncogene homolog (BRAF) melanoma and often administered in vemurafenib-resistant melanoma, is associated with response rates of less than 20% [4] .
Drug repositioning is the application of known drugs to new indications. Given the successes for a number of repositioned drugs including duloxetine, sildenafil, and thalidomide, the process has been recognized as an effective alternative to the development of novel chemical entities [5, 6] . Because repositioned drugs have often been through several stages of clinical development, and in many cases are already marketed, the time and cost required to take a drug from bench to bedside is markedly reduced. With respect to the immediate clinical need for effective melanoma therapies, drug repositioning holds the promise of a rapid solution to a pressing clinical problem. Here, we present data showing that mebendazole (MBZ), currently marketed in the USA as an oral antiparasitic drug with a remarkable safety profile, also shows promising antimelanoma growth properties in vivo.
MBZ has been used extensively to safely treat gastrointestinal parasitic infections in humans for over 50 years [7, 8] . In the treatment of common roundworms, hookworms, and whipworms, adults and children 2 years of age and older are administered 100 mg two times a day, morning and evening, for 3 days. In addition, MBZ has also shown effectiveness in the management of cystic echinococcosis (also called 'hydatid cysts') and alveolar echinococcosis. For the treatment of these conditions, MBZ is administered at higher doses for prolonged periods of time. MBZ is typically used at a dosage of 40-50 mg/kg body weight either continuously or administered as 1-6-monthly cycles separated by 10-14-day intervals. [9] . Multiple studies have shown that MBZ is generally well tolerated for extended periods of time at this dose, with rare reported adverse reactions including hepatotoxicity and gastrointestinal disturbances [10] [11] [12] .
The noted intrinsic resistance of melanoma to therapy has been attributed to the modulation of cellular survival pathways including apoptosis. We originally reported that MBZ, which acts as a microtubule-disrupting agent, is a potent inducer of phosphorylation of B-cell lymphoma 2 (BCL2) and apoptosis in melanoma cells in vitro. Here, we show that in addition to its effects on BCL2, MBZ also modulates another key antiapoptotic factor, X-linked inhibitor of apoptosis (XIAP), to promote melanoma apoptosis both in vitro and in vivo. XIAP is an important regulator of cellular apoptosis through direct binding to caspases and inhibition of their proteolytic activity [13] . Given its function, it is surmised that XIAP may play a critical role in melanoma chemoresistance. Indeed, overexpression of XIAP confers resistance to various chemotherapies in vitro [14] . XIAP expression has also been shown to increase with progressive disease stage in melanoma [15] .
Here, we show that MBZ inhibits human melanoma xenograft growth and is accompanied by reduced XIAP expression. In vitro, MBZ-mediated induction of apoptosis in melanoma cells involves enhanced interaction between XIAP and second mitochondria-derived activator of caspases/direct IAP-binding protein with low pI (SMAC/DIABLO) and subsequent proteasomal degradation of XIAP. This cellular response does not occur in cells resistant to MBZ and may serve as a potential biomarker of treatment response.
Methods

Reagents and cell lines
Human melanoma cell lines were cultured in DMEM supplemented with 10% fetal calf serum, 5 U/ml penicillin, and 5 mg/ml streptomycin. SK-Mel-19 was kindly provided by Alan Houghton (Memorial Sloan-Kettering Cancer Center, New York, New York, USA). M-14 cells were a generous gift from Gabriella Zupi (Instituto Regina Elena, Rome, Italy). A-375 was obtained from the American Type Culture Collection (St Louis, Missouri, USA). The following cell lines were provided by Dr Pamela Pollock: MM622, MM540, D08, MM329, D17, and UACC1097 (UACC1097 was supplied by the Arizona Cancer Center Cell Culture Shared Resource, Tucson, Arizona, USA). All cells were maintained in an incubator with a humidified atmosphere of 5% CO 2 at 371C. TMZ (NSC 362856) was kindly provided by the National Cancer Institute (Bethesda, Maryland, USA). MBZ and MG132 were purchased from Sigma Aldrich (St Louis, Missouri, USA).
Xenograft studies
All animals were handled in strict accordance with good animal practice as defined by the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the Public Health Service Policy on Humane Care and Use of Laboratory Animals. Animal protocols were approved by the Institutional Animal Care and Use Committee at New York University School of Medicine. Athymic female nude mice aged 4-6 weeks (Taconic, Germantown, New York, USA) were injected subcutaneously into the left flank with 2 Â 10 6 M-14 melanoma cells with 50% Matrigel (BD Biosciences, San Jose, California, USA) for tumor implantation. Mice were maintained in ventilated cages and fed/watered ad libitum with experiments carried out under an IACUC-approved protocol as well as following institutional guidelines for the proper and humane use of animals in research. After the development of a 3-5 mm tumor (within 14 days), mice were randomly divided into one of four experimental groups: 1 mg MBZ administered by a gavage every other day, 2 mg MBZ administered by a gavage every other day, 100 mg/kg TMZ administered by an intraperitoneal injection for 5 days, and dimethyl sulfoxide (DMSO) administered by an intraperitoneal injection for 5 days (mock-treated controls). Each experimental group included 10 mice; the experiment was repeated three times. Treatment was administered for 5 weeks. During this time, mice were monitored for tumor growth through twice-weekly caliper measurements of tumor diameter (determined by cross-sectional diameter) and tumor volume (using the formula a 2 Â b/2, in which a is the short diameter of the tumor and b is the long diameter of the tumor). After the full course of treatment, mice were killed by CO 2 euthanasia. Tumors were extracted and immediately frozen at -801C.
Protein extraction and western blotting
Cells and/or homogenized tumors were harvested in an extraction buffer containing 1% Triton X-100, 50 mmol/l Tris, 2 mmol/l EDTA, 150 mmol/l NaCl (pH 7.5), protease inhibitor cocktail (Roche Applied Science, Indianapolis, Indiana, USA), and phosphatase inhibitor cocktail (Sigma Aldrich). The lysates were centrifuged at 10 000g, 41C, for 10 min in a microcentrifuge with the protein concentration of supernatant determined using a protein assay kit (Bio-Rad, Hercules, California, USA). Proteins were separated by 10% SDS-PAGE and transferred onto polyvinylidenedifluoride membranes (Polyscreen; Perkin-Elmer, Waltham, Massachusetts, USA). Estimation of protein molecular weight was carried out using the Precision Plus Kaleidoscope Protein Standard (Bio-Rad). Antibodies against cleaved poly(ADP-ribose) polymerase (PARP, Cat. No. 9541), cleaved caspase 9 (Cat. No. 9501), cleaved caspase 3 (Cat. No. 9661), and XIAP (Cat. No. 2042) were obtained from Cell Signaling Technology (Danvers, Massachusetts, USA). BCL2 (Cat. No. sc-7382) and SMAC/DIABLO (Cat. No. sc-22766) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, California, USA). Phosphorylated forms of BCL2 protein appear as more slowly migrating species [16, 17] . Anti-actin (Cat. No. A2103; Sigma Aldrich) was used as a control. Immunoreactive bands were visualized using enhanced chemiluminescence detection reagent (Perkin-Elmer) and X-OMAT processing.
Immunoprecipitation
Cells were treated with MBZ for indicated times and then lysed in NP40 buffer [50 mmol/l Tris-HCl, 150 mmol/l NaCl, 1% NP40 (pH 8.0)] containing a protease inhibitor cocktail and a phosphatase inhibitor cocktail. Protein (150 mg) was combined with 10 ml anti-SMAC/DIABLO (Cat. No. sc-22766; Santa Cruz Biotechnology) or anti-XIAP (Cat. No. 9661; Cell Signaling Technology) antibodies and incubated at 41C overnight. Immobilized protein A/G slurry (100 ml; Thermo Fischer Scientific, Rockford, Illinois, USA) was added to the antigen-antibody complex and incubated at room temperature for 2 h with gentle mixing. After several washes with water, loading buffer was added to the slurry. The solution was incubated for 5 min at 951C. From each sample, 30 ml of solution was used for evaluation by SDS-PAGE gel as described above.
Following treatment with MBZ, cellular proliferation was assessed using a tetrazolium dye reduction assay (Cell-Titer 96 AQueous Non-Radioactive Cell Proliferation Assay; Promega, Madison, Wisconsin, USA) carried out according to the manufacturer's instructions as described previously. Absorbance was recorded on a microplate reader at 495 nm. In Fig. 5 , cellular proliferation was expressed as percentage with vehicle-treated cells set at 100%.
Sulforhodamine assay
The growth-inhibitory effect of MBZ was also measured using the SRB assay (Sigma Aldrich). Cells were plated in 96-well plates. The next day, MBZ was added at half-log serial dilutions (10 mmol/l to 1 nmol/l). The SRB assay was performed 72 h after addition of MBZ. Data were analyzed and GI 50 values were generated by nonlinear regression analysis with variable slope using Prism software (GraphPad Software, La Jolla, California, USA).
Statistics
Unless otherwise noted, experiments were conducted in triplicate. All data are presented as the average± SEM [18] . P values were determined using a two-sided Student's t test with unequal variance, with P less than 0.05 considered significant.
Results and discussion
Mebendazole effectively inhibits melanoma xenograft growth
We originally identified MBZ as a potent inducer of Bcl2 phosphorylation and apoptosis in melanoma cell lines [17] . On the basis of its promising in-vitro activity, we aimed to assess the ability of MBZ to suppress melanoma tumor growth in vivo using a human melanoma xenograft model established from M-14 cells. We tested four experimental groups in these studies: 1 mg MBZ by a gavage every other day, 2 mg MBZ by a gavage every other day, 100 mg/kg TMZ by an intraperitoneal injection for 5 days, and DMSO by an intraperitoneal injection for 5 days (controls). MBZ concentrations are based on upper and lower dosing equivalents used in long-term treatment regimes for hydatid parasitic cysts [19] . TMZ treatment was used as a positive control, as it is a current standard of care for melanoma. The high dose of TMZ (100 mg/kg administered daily for 5 days) was chosen as it is commonly used for preclinical melanoma studies [20] [21] [22] . The results showed that MBZ inhibited M-14 melanoma xenograft tumor growth comparably at both doses tested (tumor growth inhibition = 83 and 77%, for 1 and 2 mg dosing, respectively). These data indicate that oral MBZ inhibits tumor growth as effectively as high-dose
intraperitoneal TMZ ( Fig. 1a and b) . The efficacy of MBZ as compared with TMZ was further indicated by a significant reduction in tumor volume as shown in Fig. 1c . No obvious toxicity was observed with MBZ treatment (Fig. 1d ).
In agreement with our previous in-vitro studies, MBZ induced Bcl2 phosphorylation in vivo in response to both doses tested (Fig. 2 ). In addition, decreased levels of XIAP and enhanced cleavage of caspases 3 and 9 were also observed in mice receiving MBZ (Fig. 2) . In contrast, no effect on Bcl2 or XIAP was observed in tumors obtained from mice following treatment with TMZ or DMSO (control).
Mebendazole treatment causes X-linked inhibitor of apoptosis downregulation
Given XIAP's critical role in the regulation of apoptosis, we examined its function in MBZ-mediated apoptosis. As shown in Fig. 3a , treatment of M-14 and A-375 melanoma cells with 0.5 mmol/l MBZ results in a time-dependent decrease in XIAP protein levels first evident at 24 h following treatment. The decrease in XIAP levels in response to MBZ exposure inversely correlates with an increase in cleaved PARP (Fig. 3a) , a well-characterized marker of apoptosis. In addition to enhanced cleavage of PARP, we also observed enhanced cleavage of caspase 9 consistent with activation of the mitochondrial-mediated apoptotic pathway (Fig. 3a) .
Under conditions promoting apoptosis SMAC/DIABLO is capable of negatively regulating XIAP through selective binding to XIAP itself, thereby blocking inhibition of caspases by XIAP [23, 24] . We therefore hypothesized that promotion of melanoma apoptosis by MBZ might be achieved through alterations in XIAP's ability to interact with SMAC/DIABLO. To test this hypothesis, we immunoprecipitated XIAP from nontreated and MBZtreated M-14 melanoma cell lines, and immunoblotted for SMAC/DIABLO. As shown in Fig. 3b , a time-dependent increase in SMAC/DIABLO association with XIAP was observed in MBZ-treated cells as compared with untreated cells. This increase was initially detected 9 h after treatment. Similar results were obtained when the opposite immunoprecipitation reaction was performed (i.e. SMAC/ DIABLO immunoprecipitation, XIAP immunoblot). Altogether, these data suggest that MBZ treatment results in enhanced interaction of XIAP with SMAC/DIABLO, thereby alleviating XIAP's inhibition on apoptosis.
Mebendazole-mediated X-linked inhibitor of apoptosis degradation does not occur in mebendazole-resistant cells
Given that XIAP has been linked to melanoma chemoresistance through its antiapoptotic function, we aimed to determine whether XIAP expression could serve as a molecular marker for MBZ sensitivity in melanoma cell lines. To this end, we assessed XIAP levels in MBZ-sensitive and MBZ-resistant cell lines before and 24 h following treatment with 1 mmol/l MBZ. Interestingly, basal levels of XIAP in our panel of melanoma cell lines did not appear to be predictive of cellular response to MBZ (Fig. 4b) .
However, cells that were sensitive did show reduced levels of XIAP after treatment with MBZ, whereas resistant cells (i.e. MBZ IC 50 Z 10 mmol/l) did not (Fig. 4b ). Reduced XIAP expression in response to MBZ treatment is partially reversible upon treatment with the proteasomal inhibitor MG132 (Fig. 4a) . These data suggest that the MBZmediated decrease in XIAP levels results at least in part from its proteasomal degradation.
Modulation of X-linked inhibitor of apoptosis levels sensitizes mebendazole-resistant cells to apoptosis
Given that UACC1097 and D17 nonmutant BRAF melanoma cells are resistant to the inhibition of growth by MBZ and do not show downregulation of XIAP upon treatment with MBZ ( Fig. 4b) , we hypothesized that if XIAP was critical to MBZ-induced apoptosis, MBZresistant cells should be rendered sensitive to MBZ if XIAP levels are reduced by siRNA. As shown in Fig. 5 , siRNA knockdown of XIAP results in a significant reduction in the levels of XIAP, whereas control, scrambled siRNA has no effect in both UACC1097 and D17 melanoma cells. Reduction of XIAP protein levels in UACC1097 and D17 melanoma cells rendered them more sensitive to the growth-inhibitory effects of MBZ compared with cells treated with a scrambled siRNA (Fig. 5 ). These data are consistent with the notion that XIAP is a critical mediator of MBZ-induced apoptosis in melanoma cells.
We originally identified MBZ as a potent inducer of BCL2 phosphorylation and apoptosis in melanoma cell lines [17] . MBZ is a drug with known microtubule-disrupting properties that has been used safely as an antihelminthic agent in the treatment of parasitic infections for over 50 years [7] . We found that phosphorylation of BCL2 in response to MBZ causes a decreased association with BAX, a condition that favors apoptosis [17] . BAX oligomerization promotes permeabilization of the outer mitochondrial membrane and the subsequent release of apoptogenic proteins such as cytochrome c and SMAC/DIABLO [25] .
Our data suggest that MBZ has the potential to be repositioned as an antimelanoma agent. At concentrations achievable with oral administration, MBZ is able to effectively inhibit the proliferation of melanoma xenografts in vivo (Fig. 2) [17] . This growth inhibition may be attributable to MBZ's ability to target cellular antiapoptotic machinery and thereby promote apoptosis (Figs 2 and 3). Of particular interest is the fact that MBZ shows important pharmacokinetic properties (such as enhanced oral bioavailability and maximal plasma concentrations after oral administration that considerably exceed those necessary to induce apoptosis in melanoma cells) that make it an ideal candidate for further study in a clinical setting [26] . In addition, several published studies have reported MBZ's ability to inhibit cellular proliferation in certain other cancer cells including lung, hepatocellular, and adrenocortical carcinoma [27] [28] [29] .
Shi et al. [30] recently found that downregulation of XIAP was a predictor of cellular response to microtubuledisrupting agents. In addition to rapid phosphorylation of Bcl2 and its enhanced dissociation from BAX [17] , we have now shown that MBZ treatment of melanoma cells results in the downregulation of XIAP as well as increased interaction of remaining XIAP with SMAC/DIABLO, which has been shown previously to relieve XIAP's inhibitory effects on apoptosis (Fig. 3 ) [23, 24] . Phosphorylation of BCL2 is an early event, occurring at 3-6 h after MBZ treatment [17] . Our data show enhanced interaction between XIAP and SMAC/DIABLO by 9 h (although it is possible that this occurs at earlier time points not evaluated), followed by downregulation of XIAP at 24 h ( Fig. 1 ). Our data would suggest that this sequence of events is responsible for MBZ's ability to promote apoptosis in melanoma cells. In addition, in light of recent studies suggesting that renal cell cancer can be rendered sensitive to apoptosis through multiple targeting of XIAP and BCL2, a single agent such as MBZ that impacts both proteins might prove valuable in overcoming apoptotic resistance to therapy in melanoma [31] .
Previous studies have suggested that other microtubulebinding agents such as paclitaxel induce a decrease in XIAP levels through proteasomal degradation [32] .
In addition, recent data suggest that XIAP can function as an E3 ubiquitin ligase [33] . Furthermore, XIAP can regulate itself through autoubiquitination [34] . Several studies have also shown that XIAP agonists such as SMAC/DIABLO can trigger the degradation of XIAP [35] . Our data using the proteasomal inhibitor MG132 suggest that the reduction in XIAP protein levels observed upon treatment with MBZ is likely mediated by proteasomal degradation (Fig. 3 ).
We show that XIAP levels in response to treatment with MBZ correlate with the sensitivity of melanoma cell lines to the antiproliferative effects of MBZ (Fig. 4) . Interestingly, basal XIAP levels do not provide the same predictive value. This finding is also consistent with the report of Shi et al. [30] , who showed that sensitivity to paclitaxel and nocodazole does not correlate with pretreatment levels of XIAP. Moreover, in agreement with the results reported here for MBZ, they found that sensitivity to microtubule-targeting agents correlates with a loss of XIAP during the drug response [30] .
As key components of the cytoskeleton, microtubules are essential for cell structure, intracellular transport, mitosis, and cell division [36] . Through disruption of the mitotic spindle, classical microtubule-targeted drugs such as paclitaxel and Vinca alkaloids exert their inhibitory effect on cancer cell proliferation through inhibition of tubulin degradation and polymerization, respectively. This antitubulin mechanism results in arrest of the cell cycle at the metaphase-anaphase transition and induction of apoptosis [37, 38] . However, melanoma fails to respond sufficiently to 'classical' microtubule-targeted drugs such as paclitaxel and vinblastine [39] . Similar to the Vinca alkaloids, MBZ inhibits tubulin polymerization. However, it should be noted that MBZ possesses different tubulinbinding properties than the classical anticancer drugs. MBZ binds to the colchicines-binding site [40] , whereas paclitaxel and vinblastine bind to the paclitaxel-binding and vinblastine-binding sites, respectively [36] . Therefore, it is reasonable to suggest that MBZ has the potential to be an effective antimelanoma agent despite the disappointing results with other microtubule-disrupting agents.
In vivo, MBZ inhibits melanoma xenograft growth ( Fig. 1 ). Tumors of mice treated with MBZ show activation of the apoptotic pathway as evidenced by caspases 3 and 9 cleavage (Fig. 2 ). However, it should be noted that we did not observe regression in our in-vivo model of human melanoma. Although we showed that MBZ induces cell death in vitro and in vivo causes marked tumor growth inhibition, the question as to why we did not observe tumor regression in the M-14 melanoma xenografts still remains. It is possible that in the presence of MBZ, equilibrium exists between cellular proliferation and cellular death in these xenografts.
Previous in-vivo studies have clearly shown that MBZ is an effective antitumor agent in the treatment of lung and adrenocortical carcinomas at dosing concentrations of 1 and 2 mg [41, 42] . Our decision to use similar MBZ doses in our study were made on the basis of the efficacy of the aforementioned studies as well as our in-vitro data showing that MBZ potently inhibits melanoma cell growth and induces apoptosis at 0.5 mmol/l in M-14 melanoma cells [17] . This concentration can be achieved in humans by administering 50 mg/kg orally per day as done in the treatment of cystic and alveolar echinococcosis and is equivalent to the 1 mg MBZ dose used in our xenograft studies [43] . Our data showed that both 1 and 2 mg MBZ effectively inhibited melanoma xenograft growth, resulted in BCL2 phosphorylation, and decreased XIAP expression, and was well tolerated (Figs 1 and 2) . Because the effect of 1 mg MBZ appears to be very similar to 2 mg MBZ and 1 mg MBZ dosing clinically achievable using the dosing regimen established for the treatment of echinococcosis, we would conclude that this dose would be ideal for future clinical studies.
Our data have clinical implications for the treatment of melanoma. Our in-vivo data suggest that MBZ inhibits melanoma growth in an efficacious manner similar to TMZ (the current standard of care for nonmutated BRAF melanoma) and is well tolerated (Fig. 2) . These studies lay the groundwork for further evaluation in a clinical trial of advanced melanoma.
